Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.71 |
| ▸ | CDK1 | P06493 | 4/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.71 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | PRKACG | P22612 | 1/20 | 0.51 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058756 | 0.87 | CDK1 (0.54) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL756644 | 0.83 | CDK1 (1.00) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL539356 | 0.83 | CDK2 (0.56) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL29611365 | 0.83 | CDK1 (1.00) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL29426182 | 0.83 | CDK2 (0.56) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL17615377 | 0.81 | CDK2 (0.50) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL16080845 | 0.81 | CDK2 (0.73) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL23641811 | 0.80 | CDK1 (0.71) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL21540017 | 0.80 | CDK1 (0.71) | CDK2CDK1CCNB1CCNE1CCNA2 | |
| SCHEMBL31707890 | 0.80 | CDK2 (0.49) | CDK2CDK1CCNB1CCNE1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-3524604-B1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-01-05 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-7115589-B2 | Purine derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1259520-B1 | NOVEL PURINES | ARIAD PHARMA INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050096298-A1 | Novel perines | METCALF CHESTER A III (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1259520-A2 | NOVEL PURINES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1244679-A1 | PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020132819-A1 | Novel purinse | ARIAD PHARMACETICALS, INC. | 2002-09-19 | — | — | US | disclosed |
| WO-2001044260-A9 | NOVEL PURINES | ARIAD PHARMA INC (US) | 2002-07-04 | — | — | WO | disclosed |
| US-20020068721-A1 | Purine derivatives | ARIAD PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2001044260-A2 | NOVEL PURINES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044259-A1 | PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | CDK2 1/4885CDK1 6/4885CCNB1 29/4885 |
| US-20050096298-A1 | Novel perines | PNP, ENTPD5, NT5C2 | CDK2 3427/4885CDK1 2720/4885CCNB1 2876/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CDK2 1444/4885CDK1 2497/4885CCNB1 4047/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK2 1444/4885CDK1 2497/4885CCNB1 4047/4885 |
| US-20020068721-A1 | Purine derivatives | HPRT1, PNP, TYMP | CDK2 775/4885CDK1 434/4885CCNB1 206/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK2 1444/4885CDK1 2497/4885CCNB1 4047/4885 |
| US-20020132819-A1 | Novel purinse | PURB, NUDT15, NT5C2 | CDK2 2448/4885CDK1 2412/4885CCNB1 2817/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CDK2 1444/4885CDK1 2497/4885CCNB1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.